Start:
January 9, 2021
End:
December 2021
Enrollment:
50
The Bacille Calmette-Gurin (BCG) vaccine is used to reduce risk of tuberculosis and some other bacterial and viral infections. Studies of adults receiving the BCG vaccine suggest that the vaccine may reduce the risk for Alzheimer's. This pilot study will test if the BCG vaccine affects the amount of amyloid, a protein associated with Alzheimer's disease, in people with no cognitive impairment. All participants will receive an initial vaccine dose by injection in the arm, followed by a booster dose one month later. Participants will also provide blood samples before vaccination and nine months later for researchers to measure levels of amyloid and immune cells.
Minimum Age: 50 Years
Maximum Age: 80 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Mindful Diagnostics and Therapeutics, LLC
Source: ClinicalTrials.gov ID: NCT04449926
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health